

*In response to the New England Journal of Medicine published report regarding vitamin E and donepezil (Aricept®) in the treatment of mild cognitive impairment (MCI).*

I think the bottom line message is that results from past studies involving individuals who already have Alzheimer's disease, are mixed. However, PREADVISE is a primary prevention trial involving participants who are cognitively healthy. The potential of anti-oxidants, like vitamin E and selenium, in the **prevention** of Alzheimer's disease in a cognitively healthy population has not been demonstrated in a large randomized control trial like PREADVISE. Therefore, the original rationale used in designing our PREADVISE prevention trial is still valid. Many researchers believe that prevention is the key to Alzheimer's disease, and may be a more attainable goal than effectively treating the disease once it has begun.

William R. Markesbery, M.D.  
PREADVISE Principal Investigator  
Professor of Neurology and Pathology  
Director, Sanders-Brown Center on Aging  
Commonwealth Chair on Aging